U.S. COMPANY FILING
ABBOTT LABORATORIES — Form 10-Q filed 2026-04-29
Filing text preview
Abbott's Q1 2026 net sales rose 7.8% to $11.16B, but net earnings fell 18.7% to $1.08B due to higher costs. The company completed the $20.6B acquisition of Exact Sciences, funded by $20B debt, expanding into cancer diagnostics. Long-term debt surged, and operating margin declined.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record